NCT01828086 - Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Chronic Plaque-type Psoriasis

Interventions

BIOLOGICAL

CJM112

Monoclonal antibody

BIOLOGICAL

Secukinumab

Monoclonal antibody

OTHER

Placebo

Liquid for subcutaneous injection without active drug.

Trial Locations (18)

19103

Novartis Investigative Site, Philadelphia

27612

Novartis Investigative Site, Raleigh

32809

Novartis Investigative Site, Orlando

33136

Novartis Investigative Site, Miami

33175

Novartis Investigative Site, Miami

33609

Novartis Investigative Site, Tampa

36207

Novartis Investigative Site, Anniston

45255

Novartis Investigative Site, Cincinnati

46256

Novartis Investigative Site, Indianapolis

61761

Novartis Investigative Site, Normal

66211

Novartis Investigative Site, Overland Park

70526

Novartis Investigative Site, Crowley

73112

Novartis Investigative Site, Oklahoma City

78229

Novartis Investigative Site, San Antonio

78759

Novartis Investigative Site, Austin

91436

Novartis Investigative Site, Encino

91606

Novartis Investigative Site, North Hollywood

92801

Novartis Investigative Site, Anaheim